Orforglipron
7 articles on Orforglipron, written by Shotlee and medically reviewed for clinical accuracy.
Eli Lilly Eyes India Rollout for Oral Obesity Drug Orforglipron
US drugmaker Eli Lilly is set to bring orforglipron, a game-changing oral weight-loss pill, to India following successful global trials that included Indian patients. With obesity rates surging, this daily GLP-1 therapy promises easier access than injectables like Mounjaro. Explore the trial data, market insights, and what it means for patients.
5 min read
Foundayo: Lilly's New Oral GLP-1 Pill for Weight Loss Now in US
Eli Lilly's Foundayo, a groundbreaking once-daily oral GLP-1 pill for weight loss, is now shipping nationwide in the US following FDA approval. Backed by the ATTAIN trials, it delivered an average 27-pound loss at the highest dose. Discover access options, pricing, and what patients need to know.
5 min read
What Is Orforglipron? New Oral Weight-Loss Pill Trial Results
A groundbreaking phase 3 trial shows orforglipron, a new daily oral weight-loss pill, surpassing oral semaglutide in blood sugar control and weight reduction for type 2 diabetes patients. This small-molecule GLP-1 agonist offers advantages over injectables like Ozempic by eliminating needles and refrigeration needs. However, higher gastrointestinal side effects raise questions about long-term tolerability.
5 min read
Eli Lilly's Employer Connect: Unlocking GLP-1 Demand
Eli Lilly is dominating the GLP-1 market with 25% projected growth in 2026, outpacing Novo Nordisk's decline. Their new Employer Connect platform could unlock massive demand for Zepbound by filling employer coverage gaps. Meanwhile, orforglipron shows superior results over Rybelsus in key trials.
5 min read
Eli Lilly's Orforglipron: More Effective GLP-1 Pill for Weight Loss?
Eli Lilly's investigational GLP-1 pill, orforglipron, demonstrated greater weight loss and blood sugar control than oral semaglutide in a major phase 3 trial for type 2 diabetes. Patients lost 6-8% body weight compared to 4-5%, though with higher GI side effects. This could signal a shift toward more effective oral therapies.
6 min read
Lilly Stockpiles $1.5B Orforglipron Ahead of FDA Approval Signal
Eli Lilly is sending a clear signal of confidence in its upcoming GLP-1 obesity pill, orforglipron, by stockpiling $1.5 billion worth of inventory ahead of FDA approval. This move, up from $550 million last year, anticipates robust demand without the supply chain issues that plagued injectables like Wegovy from 2022-2024. Here's what it means for patients seeking oral weight loss options.
5 min read
Eli Lilly Shares Face Pressure Amid GLP-1 Market Shifts
Eli Lilly posted blockbuster Q4 2025 results with $19.29B revenue, yet shares near $1,020 face selling pressure from compounded semaglutide competition and government pricing initiatives. Hims & Hers' $49 pill undercuts Zepbound's $299 intro dose, signaling shifts in the GLP-1 market. Investors eye Orforglipron's FDA decision amid pipeline cuts.
5 min read